Kronos Bio, Inc. (KRON) Misses Q2 EPS by 6c

Kronos Bio, Inc. (NASDAQ: KRON) reported Q2 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.67 million.

For earnings history and earnings-related data on Kronos Bio, Inc. (KRON) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c